CRPC & 'Drug Repositioning'
with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users.[2] It costs $163,381 per year for the average patient." [6a]
[6b] Pazopanib
"(trade name Votrient
with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users.[2] It costs $163,381 per year for the average patient." [6a]
[6b] Pazopanib
"(trade name Votrient